Morepen Laboratories LimitedNSE: MOREPENLAB

Morepen Laboratories Limited Press Release Sep 28 2026

· Issued by Morepen Laboratories Limited via NSE India

Filed with NSE · · 3 pages · English

Summary by 6ix AI

Morepen Laboratories Limited has submitted its first Abbreviated New Drug Application to the U.S. FDA for Sitagliptin Tablets, marking a significant milestone in its integrated CDMO capabilities. This submission enhances Morepen's expertise in API and finished dosage development, supporting specialized CDMO opportunities across regulated markets. The company aims to build on this foundation through customer development programs and technology transfer, expanding its capabilities in global pharmaceutical partnerships.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Morepen Laboratories Limited on 6ix

Earlier from Morepen Laboratories

Later from Morepen Laboratories

All Morepen Laboratories news releases